Ms. Anastasi provides business development leadership to create and foster priority relationships in the medical device and diagnostic marketplace, developing customized programs to meet medical device client needs. She has over twenty years of experience in the medical device industry, with over fifteen years specifically focused on medical device regulations.
Prior to joining the company in 2007, she held senior management roles for medical device companies focused in orthopedics, cardiovascular, general hospital, and general surgical devices. In diagnostics, she held senior positions at companies involved in the development of infectious disease and genetic-based products.
She is actively involved in medical device industry groups, including AdvaMed, OCTANe and MDMA, where she regularly speaks and participates in medical device focused panels and discussions.
John Babitt is the EY MedTech leader for the Americas. John is also the Life Sciences Leader for Transaction Advisory Services, US. He has over 20 years of experience, all in the healthcare industry. He originally joined EY in 1995.
Prior to re-joining EY, John was CFO of a publicly traded medical technology company and was responsible for all financial and operational aspects, including capital raising and negotiating and structuring numerous collaborations and licensing arrangements. He has operations experience in combination products, biologics, cellular therapies, cardiac surgery and interventional cardiology.
John received a bachelor’s in Accounting and a MBA in Finance from the University of Miami.
John Brennan is currently the Director of Regulations and Industrial Policy at MedTech Europe. John joined Eucomed in August 2008 as Director of Technical & Regulatory Affairs, after spending five years at the European Commission working in the Unit responsible for the European medical devices legislation. During his time at the Commission he also had particular experience in international regulatory cooperation (GHTF). John has over 20 years experience both on the regulatory and the industrial sides of the healthcare industry.
Prior to coming to Brussels John worked in, and managed, the Irish Notified Body, NSAI (10 years) gaining extensive European and international experience in the design approval of high-risk devices and quality management systems. He sat on the working group which developed the international quality management systems standard for medical devices, ISO 13485. He began his career in the industry with five years experience spanning the in vitro diagnostic, pharmaceutical and medical device industries.
John is a science graduate from Dublin, Ireland, with added post-graduate studies in quality control and environmental engineering.
Patrick Brennan is Assistant Vice President for AdvaMed Accel, where is he is responsible for representing the interests of small medical technology companies through policy development, advocacy initiatives, networking opportunities and educational offerings.
Peter Byloos joined Gimv in 2015 as Business Development Partner for Health & Care. He is a Medical Doctor from the University of Leuven and holds a Master of Science in Management from the Boston University. In his last role, Peter was CEO of Handicare, a Norwegian PE-backed international solution provider of technical aids (e.g. wheelchairs, stairlifts) for the elderly and disabled. Before that he held several executive positions for large US Medical Device corporations, i.a. as the President EMEA at CR Bard.
David has more than 30 years of experience in the health care industry. Prior to co-founding Innovation In Medtech, LLC, he served as Vice President, Content and Managing Director, Medical Devices for Elsevier Business Intelligence, A Reed Elsevier Company, now part of Informa Business Information, where he wrote extensively on the medical device industry for Windhover’s monthly publications, IN VIVO and START-UP. He is also a frequent speaker before various companies and industry trade groups.
Prior to joining Elsevier, David worked for nearly 20 years at Windhover Information Inc., a company he founded with his partner, Roger Longman, which spun out the publications business of The Wilkerson Group, a leading management consulting firm at the time.
Chris is Vice President of Corporate Development for Medtronic, with responsibility for acquisitions, dispositions and minority investments. During 2014, Chris led the corporate development efforts for Medtronic’s $50B acquisition of Covidien as well for Medtronic’s acquisition of both Sapiens and NGC, for $200MM and $350MM respectively.
Prior to 2014, Chris was CEO of Alesia Capital Services, a management consulting firm for Fortune 500 companies, including Medtronic, Goldman Sachs, Ally, Macquarie Capital and Terex. From 1995 to 2011, Chris led M&A teams within several businesses at GE Capital, closing acquisitions totaling more than $60B across 200+ transactions in the US, Canada, Europe, Asia and Latin America.
Inga is a Principal in the Healthcare Ventures team, specialising in investments across medical devices, therapeutics, diagnostics, and healthcare, including digital health. She is currently a Director at Puridify and Ieso Digital Health and a board observer at Veryan Medical, Oxular, and ApcinteX.
Previously she worked in business development and technology transfer at the London Bioscience Innovation Centre/Royal Veterinary College in London, commercializing research, sourcing and building industry collaborations. She completed a DPhil and MSc in Neuroscience from the University of Oxford, sponsored by the Wellcome Trust, developing translational models of disease using a range of molecular biology, genetics, electrophysiology, imaging and behavioural techniques. Her first degree was Natural Sciences from the University of Cambridge.
Christopher de Souza, PhD, MBA, is a Director at Broadview Ventures. He brings to this role over 20 years experience in cardiovascular and metabolic related biopharmaceutical R&D, corporate strategy and business development.
Christopher started his pharmaceutical career at Novartis as a senior scientist in the Metabolic and Cardiovascular Diseases group and then as Director of Strategic Alliances with responsibilities for therapeutic area strategy, business development and alliance management. After Novartis, Christopher was Vice President of Business Development at SkyePharma US Inc., a drug delivery company, where he was responsible for out-licensing the company’s clinical assets and drug delivery technologies. Christopher also founded a business development consulting practice with several clients including JSB-Partners, Diagnostics For All and Metaome.
Christopher received a Masters in zoology from the University of Bombay, a PhD in physiology from Louisiana State University and an MBA from Rutgers University. He completed his post-doctoral training at The Upjohn Company and the Joslin Diabetes Center/Harvard Medical School.
Christopher currently serves on the boards of Acesion, Allosteros, CellAegis, DecImmune, Gila Therapeutics, GI Windows, Pulmokine and VentriNova.
Outside of Broadview Ventures, Christopher serves on the board of MassBio and on the grant review committees of the British Heart Foundation and NIH/NHLBI.
Professor of Medicine and Professor of Engineering at Stanford University; Director, Center for Cardiovascular Technology and Director of the Core Cardiovascular Analysis Lab, Stanford University Medical Center
Peter serves as the Director of the Interventional Cardiology Research Laboratory at Stanford Medical School. He has led or participated in numerous clinical trials for new medical devices and serves on the FDA Medical Device Advisory Panel.
Peter has a PhD in biomedical engineering and has advised dozens of medical device startups and multinational healthcare companies in the design and development of new devices, diagnostics and therapies in cardiology, orthopedics, pulmonary disease, and other areas.
Peter holds an MD and PhD from Dartmouth, an RA from Stanford, an MS from Rensselaer and a BS from Santa Clara.
Paul Grand is MedTech Innovator’s CEO. He founded and has managed MedTech Innovator as a program within RCT Ventures for the past four years. In 2016, with the financial support of RCT and other sponsors, Paul left to run MedTech Innovator as a stand-alone company. He has spent the last eleven years as Managing Director for RCT Ventures, the investment arm of Research Corporation Technologies, Inc. At RCT, Paul’s focus has been medical device investments and programs to encourage innovation and commercialization of early stage technologies at institutions like UCLA, Stanford, USC, UCSF, UCSD, CU, Utah, UBC, and UW. He drove investments in incubators like Coronis Medical Ventures and Option 3 as well as grants to medtech fellowship programs at UCLA and Stanford Biodesign and pioneered the scholarship program for startups to present at AdvaMed. Paul served as an investment advisor to the LARTA NIH Commercialization Assistance Program for SBIR program awardees and is on the Oversight Committees for the Coulter Translational Research Partnership Programs at USC and UW.
Jim is a Partner at Seroba Life Sciences and has extensive operational experience spanning 29 years in medical device design, development and commercialization. Jim joined Seroba in August 2016 and focuses primarily on Medtech investments.
Prior to joining the firm, Jim served as CEO in multiple medical device start-ups. He founded and served as CEO for both Apica Cardiovascular Ltd., a Seroba investee company, and for APK Advanced Medical Technologies, Inc. (APK). APK was founded in 2013 and is developing an access platform for implantation of Mechanical Circulatory Support Systems. Thoratec Corporation, Pleasanton, California, acquired both Apica Cardiovascular and APK.
Previously, Jim served as CEO for MitralSolutions, Inc., another venture backed start-up pioneering new technology for minimally invasive mitral valve repair, which exited to St. Jude Medical in 2009. Jim previously held VP and Director level positions in Bioheart, Medtronic, AVE, Perclose, and Guidant.
Currently Jim serves as Board Chairperson for Novate Medical Limited, Galway, Ireland and is a member of the Wallace Coulter Foundation Oversight committee in Atlanta, Georgia, where he participates in mentoring new entrepreneurs in their development of university-based technologies into successful medical device companies.
Jim holds a B.A. degree from Furman University, Greenville, S.C. and served in the United States Military following graduation for 7 years.
Tim has more than 25 years of international management experience in the life sciences industry in both public and private companies. During his time at Abingworth Tim has taken board roles in a number of companies including Astex, Fovea, Lombard Medical, MEDIAN Technologies, Pixium Vision, PowderMed, Proteon Therapeutics, Sientra and Stanmore Implants.
Before joining Abingworth in 2005 he was Chief Executive of the Abingworth portfolio company, Astex Therapeutics. Tim was with Astex for over five years and was instrumental in establishing it as one of the leading UK biotechnology companies. Previously, Tim was Chief Executive of two divisions of the publicly-listed medical technology company, Datascope Corp. Prior to Datascope, he held a number of other senior management positions in the US and Europe, including CEO of Thackray Inc and General Manager Baxter UK. Tim has a BSc from Exeter University and an MBA from INSEAD.
Prior to joining FIRE1, Hanley held senior management positions with ResMed, including leading the Company’s Chronic Disease Management Solutions division, its Cardiology business, and its Ventures and Initiatives business units.
Prior to ResMed, he was CEO and co-founder of BiancaMed, a UCD spin-out company which commercialised a novel method to provide connected health solutions, and was acquired by ResMed in 2011. Hanley received a PhD in Chemical Engineering from the University of Pennsylvania, an MBA from INSEAD, and a First Class Honours B.E. from University College Dublin.
Hunt Henrie joined Locust Walk in 2017 after 15 years at Ferghana Partners where he started and led the MedTech and Financing activities. At Locust Walk Hunt is responsible for the firm’s MedTech practice and will leverage his financing experience to help Locust Walk engage in selected financing activities.
Hunt is an experienced financial, strategic and biomedical executive with over 30 years of broad-based global financial, investment banking, private equity and corporate operating experience, of which the last 25 have been in healthcare. Hunt began his career with Chase Manhattan and was a founding member of Chase’s European Mezzanine Capital Group which later became Chase Capital Partners Europe, and played a crucial role in the early success of Chase Securities’ penetration of the US high yield market in 1993-1994. Hunt spent six years in the biomedical industry with Instrumentation Laboratory where he was Managing Director for Worldwide Corporate Finance, CFO of IL’s US subsidiary and a member of the Corporate Executive Committee. Hunt has led the raising and investing of more than $6 billion in capital in support of M&A, principal investing and IPO activities, and has been involved in over $5 billion of M&A transactions.
Hunt graduated cum laude with a BA in International Relations from Boston University; he a received a Masters in International Economics from Johns Hopkins Nitze School of Advanced International Studies (SAIS); and achieved an Executive Certificate in Financial Management from the Graduate School of Business of Stanford University.
Gonz is a global entrepreneur who is currently scouting the medtech world for exciting new technologies to start his next venture.
He has been the CEO of Stentys, a company he co-founded, bringing it from inception to a successful commercial public company. In the eleven years of his tenure, he raised close to $100M in funding from both private and public investors, managed several CE Marking dossiers and an FDA IDE approval, organized multiple randomized trials and ran the commercial organization. Prior to Stentys, Gonz worked at J&J in the Cordis Endovascular franchise, where he was a sales rep and a finance controller. He started his career in North America in the auto industry where he was quickly promoted to be in charge of the 180 production employees of a new manufacturing plant.
Gonz holds an MBA from INSEAD and a Master of Science from Ecole Centrale in Paris.
Christian joined Wellington Partners in 2016 as a Principal in the Life Sciences Team.
Christian obtained his MSc degree in Molecular Biotechnology from the Technical University of Munich and was awarded a PhD with distinction in Medical Science and Technology from the Technical University of Munich for his work on patient-specific induced pluripotent stem cells. The key articles generated in the context of his PhD were published in the New England Journal of Medicine, EMBO Molecular Medicine and FASEB Journal and have so far been cited more than 1000 times. In 2013, the thesis was recognized with the “Outstanding PhD thesis award” by the Luxembourg National Research Fund. During the course of his PhD, Christian was supporting the Life Science Team of Atlas Venture in Munich.
Prior to joining Wellington, Christian was a Senior Investment Manager with High-Tech Gründerfonds, the largest german seed investor with 576 Mio. € under management, where he completed and led the early-stage investments in coramaze technologies, WISEneuro, Amal Therapeutics, CuneSoft, PS Biotech, perora, Senostic, Rigontec and Dolosys. Christian was serving as a Board Director at coramaze technologies , as well as a Board Observer at Amal, WISEneuro and Rigontec.
Albert Lauritano is Director, Technology Licensing & Collaboration for BD Technologies, the corporate technology innovation center for BD. He is responsible for technology scouting, acquisition, management, partnership and commercialization activities including the management of BD’s life science incubator and execution of innovation strategy. He is also a member of BD’s Corporate Development and University Relations MBA Recruitment teams. Al joined BD in 2003 and has over 35 years of experience in the pharmaceutical, biotechnology and medical technology industries.
Prior to joining BD, he held executive business development positions at Amylin Pharmaceuticals, Icagen and D-Pharm Ltd after starting his career at Novo Nordisk Pharmaceuticals where he served in senior clinical, marketing and business development positions in the US, Canada, Europe and Japan. Al has a BS in Biology from Fairleigh Dickinson University and an MS in Pharmacology from Rutgers University; he has published widely in the field of diabetes. He is a Certified Licensing Professional and a member of Licensing Executive Society and Association of University Technology Managers.
Eithne is an associate partner within the EMEIA Advisory Life Sciences team. She joined EY in the UK in 2013, with 25+ years of consulting experience. Eithne has led EY’s proposition in working with Medical Devices & In Vitro Diagnostics Manufacturers in structuring their response to EU MDR. She has to date led the delivery of a number of EY’s projects to support clients to undertake their gap/impact assessments, build their remediation response and to plan for implementation. She has also acted as Technical Lead to other EY teams in delivery of the EY/YE EU MDR proposition. Eithne has delivered a number of seminars on behalf of both MedTech Europe and AdvaMed to members on shaping a response to the new legislation. She has presented to the Leadership teams of multi-national organisations as they engage with their business teams to formulate their responses.
Prior to EU MDR, Eithne consulted for 25+ years in the Life Sciences sector (Pharma, BioPharma, MedTech, Consumer HC clients) across the value chain.
Jason Lettmann is a Partner of Lightstone Ventures as well as a Partner on the Life Science team at Morgenthaler Ventures. Jason invests in biopharmaceutical and medical device companies and brings over 15 years of operating and venture experience in the life science sector. Jason currently serves on the Board of Directors of Alexo Therapeutics, FIRE1, Promedior, Ra Pharmaceuticals, Relievant Medsystems, Second Genome, Spinewave and Vapotherm. Jason also recently established Lightstone’s Europe office in Dublin, Ireland, to expand the firm’s investment activities to Europe and currently serves as Director of Lightstone Capital Management Ireland Ltd.
Before joining Morgenthaler in 2009, Jason was a Vice President at Split Rock Partners where he focused on early-stage venture investments in medical devices and the life sciences. During his time at Split Rock, Jason was a board observer at Ardian (acquired by Medtronic in 2011) and Cabochon Aesthetics (acquired by Ulthera in 2014) as well as actively involved with the firm’s investments in Atritech (acquired by Boston Scientific), Entellus Medical (NASDAQ: ENTL), and Evalve (acquired by Abbott Labs). Jason was also previously a co-founder and on the Board of Tarsus Medical before its acquisition by Integra Life Sciences in 2013 as well as involved with the founding of Zyga Technologies.
Prior to co-founding Innovation In Medtech, Stephen Levin served as Editor-in-Chief of Medical Devices for Elsevier Business Intelligence, where he directed the company’s editorial coverage of the medical device industry, following Elsevier’s acquisition of Windhover Information in 2008. This included managing the device content for the following publications: IN VIVO, START-UP, MEDTECH INSIGHT, The Gray Sheet, and The Silver Sheet, along with the IN3 medical device partnering conference series. Stephen joined Windhover Information in 1997, where as Executive Editor, he specialized in covering the device industry, distribution, and legal issues. He also served as the company’s General Counsel. He also formerly was an Editor of Health Industry Today, a leading publication in the health care industry.
Prior to joining Windhover, Stephen was Senior Counsel to the US Senate Permanent Subcommittee on Investigations, where he directed Senate investigations into a wide variety of areas including health care fraud and abuse, international organized crime, and corruption in federal contracting programs, while also participating in other Senate investigations including the Whitewater inquiry. Before joining the Subcommittee, he was with the Federal Election Commission (enforcement and regulatory counsel) and the Department of Justice (international criminal law).
Justin Lynch is a Partner in Fountain Healthcare Partners and also serves as the CFO of the firm. He joined the team in early 2007 prior to the launch of Fund I in 2008. Justin has a BA in Accounting & Finance from Dublin City University, an MBA from Trinity College Dublin and is a member of the Chartered Institute of Management Accountants. He has over 25 years experience in capital markets, corporate finance, entrepreneurial and venture investing across multiple sectors, the latter half in life science. Justin has a particular interest in the medical device sector and leads the firms investments in Neuravi and Vivasure Medical where he also serves as a board member.
Josh is a General Partner with New Enterprise Associates, and is also the Founder & Chief Executive Officer of the medical device incubator ExploraMed. He also serves as Chairman of the Board for ExploraMed, Nuelle, Moximed, and NeoTract, and is a member of the board of directors for Ceterix, Coravin, and Intrinsic Therapeutics. In addition, Josh also serves as a Consulting Professor of Medicine at Stanford University Medical School and is Co-Founder of Stanford’s Biodesign Innovation Program.
Mirren is a Senior Director, New Ventures and Transactions, for Medical Devices based in the Johnson & Johnson Innovation Centre in London. In this role he leads investments that Johnson & Johnson Innovation makes in innovative early stage medical devices and enabling technologies across Europe, Middle East and Africa.
He joined Johnson & Johnson over 3 years ago and prior to this Mirren was a key member of the healthcare practice at The Boston Consulting Group in London, advising pharma, medtech, payers and providers. Over the past few years, he has also been an advisor for a number of healthcare start-ups.
Mirren is a trained surgeon with expertise in General Surgery and Plastics & Reconstructive Surgery, and held surgical posts at major teaching hospitals including University College Hospital, Royal Free Hospital and St George’s Hospital. He qualified as a doctor at St. George’s Medical School, University of London, and undertook research on innovative surgical technologies, including on virtual reality simulators and motion analysis, with Lord Ara Darzi at Imperial College, London. He is a Member of the Royal College of Surgeons of England and also received an MBA from London Business School.
Jennifer McMahon joined the Seroba team in 2011. She graduated from UCD with an honours degree in Pharmacology in 2010. Jennifer then entered a masters degree programme in Biotechnology and Business to further her interest in the interface of biomedical science with commercialisation. Having placed first in her masters degree in 2011, Jennifer then joined Seroba’s Investment Team as an Investment Analyst and was appointed Senior Analyst in 2014 and Associate in 2016. Jennifer sits on the board of Biosensia Limited.
As Vice President of Business Development and a member of the Medical Devices Group Operating Committee, Susan has responsibility for strategic planning and licensing & acquisitions for the Medical Devices Group.
Susan joined Johnson & Johnson as a college recruit in the finance organization. During her tenure in the Corporation, she transitioned through a number of positions with increasing responsibility through six operating companies, primarily within finance and new business development. Susan has been involved in a number of significant transactions within MD&D.
Ms. Morano received her BS in accounting from Villanova University and an MBA from Columbia University.
John’s career spans twenty years, with extensive experience leading and working with international healthcare and emerging medical technology companies as an executive manager, board member, private equity investor and corporate financier.
Prior to joining Quanta, John was an Investment Director at NBGI Ventures, where he was closely involved, both as a board member and a venture investor, with a range of start-ups that successfully developed and launched innovative medical technologies. Before that, John served as CFO and Head of Business Development at Nitec Pharma, worked as an investment professional at Atlas Venture and was a healthcare corporate finance officer at Nomura International in London.
He is a graduate of the University of Chicago and currently sits on the i4i selection panel for the NHS National Institute for Health Research.
Dr. Oesterle is a former Senior Vice President for Medtronic, and brings to NEA more than two decades of experience spanning health technology investment, corporate strategy, and general management.
Antoine Papiernik is a Managing Partner at Sofinnova Partners, which he joined in 1997. Antoine has been an initial investor and active board member in public companies like Actelion, Auris, ProQR, NovusPharma (then sold to CTI), Movetis (then sold to Shire), Mainstay, Pixium Vision and Stentys, which went public respectively on the Zürich stock exchange, the NASDAQ, the Milan Nuovo Mercato, the Belgium Stock Exchange, the Dublin Stock Exchange and EuroNext Paris, in Cotherix (initially NASDAQ listed, then sold to Actelion), CoreValve (sold to Medtronic), Fovea (sold to Sanofi Aventis) and Ethical Oncology Science (EOS, sold to Clovis Oncology). He has also invested in and is a board member of private companies ReCor, MD Start, Shockwave Medical, and Reflexion Medical and ProQR.
Dr. Martin Pfister studied biopharmacology at the University of Greifswald and New York University, and earned a doctorate in immunology at the University of Leipzig. Prior to joining High-Tech Grunderfonds Management, Pfister served as Managing Director of the Saxony State Ministry of the Economy and Labour’s coordination office for biotechnology & pharmaceuticals.
Stan currently serves as Vice President, Advanced Technology & Discovery at Edwards Lifesciences. He joined the company in 2004 when Edwards acquired Percutaneous Valve Technologies, Inc. (PVT), of which he was co-founder, Executive Vice President and COO. PVT has pioneered the development of transcatheter heart valves.
Stan spent over 17 years of his medical device development career at Johnson & Johnson, where he held positions in Engineering, R&D and Business Development at Johnson & Johnson Interventional Systems (JJIS), SITE Microsurgical and Johnson & Johnson Ultrasound.
Previously Managing Director of Ethicon and Vice President (Europe) of Johnson & Johnson subsidiary Critikon.
Josep L.l. Sanfeliu focuses on medtech investments and on structuring transactions.
Josep serves on the board of MedLumics, Dermalumics and CVRx. Formerly, he was board observer at Endosense and board member at Sabir Medical.
Josep has over 15 years of experience in law, corporate finance and business development in connection with entrepreneurs and with intellectual propertyrelated companies. Before joining Ysios, Josep worked for the pharma and healthcare industries, in areas such as business and corporate development. This included managerial positions at Almirall and SAR-Quavitae. Joe also worked at Cuatrecasas, KPMG and Eurohold Corporate Finance, where he was involved in mergers and acquisitions, and financing of innovation and technology.
Josep holds a degree in Law from Universitat Pompeu Fabra of Barcelona, a Master of Laws (LL.M) degree from the University of Michigan at Ann Arbor, and an MBA (Global Executive MBA) from IESE (University of Navarra).
Diana is Co-Founder & Former Managing Partner at 360 Capital Partners. She has 15 years of venture capital experience, has invested in a significant number of companies in Italy and all over Europe not only in the medical device sector, and generated several exits as IPO and M&A transactions. She has strong knowledge of the venture capital community in Italy/Europe.
She has a Msc in Engineering from LaSapienza, and an MBA from Luiss University.
Dr. Daniel Schultz joined Greenleaf following a distinguished 35-year career devoted to supporting and advancing Americans’ public health as a physician, teacher, Food and Drug Administration (FDA) official, and member of the US Public Health Service (USPHS). He has been recognized many times for his contributions and dedication to public health.
Dan continues his commitment to public health at Greenleaf as Principal of Medical Devices & Combination Products, where he provides strategic consulting services and works with Greenleaf clients to bring safe and innovative devices to patients.
As Director of the Center for Devices and Radiological Health (CDRH) at FDA from 2004–2009, Dan was responsible for seven FDA offices and more than 1,000 agency employees. He led the development, implementation, and evaluation of regulatory policies concerning medical devices and radiation-emitting products.
Dan began his 15-year FDA career in 1994 as a Medical Officer in the General Surgery Devices branch of the CDRH’s Office of Device Evaluation. In 1995, he advanced to Chief Medical Officer in the Office of Device Evaluation in the division of Reproductive, Abdominal, ENT, and Radiological Devices. He served as Division Director from 1998–2001. Dan became Deputy Director for Clinical and Review Policy in the Office of Device Evaluation in 2001 and Director of the Office of Device Evaluation the following year.
A New York City native, Dan is a graduate of the City College of New York. He received his M.D. from the University of Pittsburgh and is board certified in Surgery and Family Practice.
Dan Sheehan manages the activities of Medtronic/Covidien Ventures. Dan is passionate about working with the managers of entrepreneurial companies and understands the complexity of commercializing new medical technologies. His background includes both venture capital investing and operating company management roles in the healthcare sector. Prior to Covidien, Dan was a General Partner with Affinity Capital Management, a healthcare oriented venture capital firm in Minneapolis. He has also managed the business development and strategic marketing efforts for Steris Corporation, a provider of infection prevention and surgical support products for the healthcare and life sciences sectors. He has been a member of the Board of Directors of many portfolio companies. He is a graduate of Fordham University and Columbia Business School.
Simonton received his medical degree at Harvard and did his internship and residency at the University of California, San Francisco and his fellowship at Duke University Medical Center, in Durham, NC.
Damien is co-founder, President and Managing Partner of Endeavour Vision. With more than a decade of Entrepreneurship and Venture Capital experience, Damien has developed a solid experience in creating and building businesses in a number of sectors including Information Technologies, Telecom and Medical Technologies. On behalf of Endeavour, Damien currently serves on the Board of CeQur and Symetis and was previously Chairman of Bitplane (acquired by Andor Technology AND:LN), Chairman of GeneSystems (acquired by Pall Corp, ticker PLL) and Director of Cirpack (acquired by Thomson, ticket TOC).
Before co-founding Endeavour Vision, Damien was the founder and Director of the Start-up and Spin-off Program from the Swiss Federal Institute of Technology in Lausanne (EPFL). During his tenure, more than 35 spin-offs were launched, and the Institute strengthened its emphasis on start-up development. In parallel, he served as expert for new ventures creation at the Swiss Federal Commission for Technology and Innovation (CTI) in Bern.
Damien holds a business education (MTE) from IMD, Lausanne, Switzerland and is an Engineer in micro-technology from the Swiss Federal Institute of Technology (EPFL) with honours. He worked as International Fellow on projects in the field of Medical imaging over the Internet at the Stanford Research Institute in California (SRI International). Damien also served as an Officer in the French Air Force.
Martien spearheads the medical device-related activities at Forbion. He was responsible for the recent exit of Santaris Pharma AS to Roche in August 2014 for up to USD 450 million, the sale of Circulite to Heartware in December 2013 for up to USD 350 million, and of Pathway Medical Technologies, sold to Bayer Medrad in 2011 for USD 125 million.
Zeev Zehavi, Vice President, Venture Investments, joined Johnson & Johnson Innovation – JJDC, Inc. (JJDC) in 1999. Mr. Zehavi is based out of offices in Israel and Belgium.
Mr. Zehavi’s background covers an extensive array of health care and related businesses. He spent over ten years with Teva Pharmaceutical Industries, Ltd., including a five-year assignment as President of the bulk chemical business in North America. He returned to Israel as President of Clal Pharmaceutical Industries (CPI) for four years before starting his own consulting business, Pharma Zee, Ltd. While operating this consultant business for medical device and pharmaceutical start-up companies, Mr. Zehavi initiated contacts with various Johnson & Johnson companies.
Mr. Zehavi holds a Bachelor of Science from Hebrew University of Jerusalem and a Master of Business Administration in Marketing and Finance from Tel Aviv University. He is fluent in Hebrew, English, and Arabic.